Search clinical trials for: Oral Azacitidine

Total 18007 results

The First Affiliated Hospital of Soochow University

Recruiting

Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

High Risk Acute Myeloid Leukemia | Intermediate Risk Acute Myeloid Leukemia

China
Peking University People's Hospital
Henan Cancer Hospital; Wuhan Union Hospital, China; Zhejiang University; Peking... and other collaborators

Not yet recruiting

The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

Chronic Myeloid Leukemia

China
Virginia Commonwealth University

Not yet recruiting

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality (REMAIN1)

Acute Myeloid Leukemia

United States
Centre Hospitalier Universitaire de Nice

Recruiting

Oral Azacitidine Maintenance Post-CPX 351 (ORAZ-351)

Acute Myeloid Leukemia

France
Bristol-Myers Squibb

Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Korea, Republic of
AbbVie

Recruiting

A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy (VERO)

Acute Myeloid Leukemia

Italy
French Innovative Leukemia Organisation
Acute Leukemia French Association

Recruiting

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (OGILAR)

AML, Adult | Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITD

France
The First Affiliated Hospital of Soochow University

Recruiting

VA vs DA for Newly Diagnosed Hig-risk AML

Acute Myeloid Leukemia

China
Servier Affaires Médicales

Recruiting

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Acute Myeloid Leukemia (AML)

Netherlands, Italy, Austria, France
Otsuka Australia Pharmaceutical Pty Ltd

Recruiting

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia (PREFER-HMA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Patient Preference

New Zealand, Australia
Groupe Francophone des Myelodysplasies
Bristol-Myers Squibb; AbbVie

Recruiting

Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Untreated Myelodysplastic Syndrome

France
AbbVie

Recruiting

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia (ESVECO)

Acute Myeloid Leukemia

Colombia
Bristol-Myers Squibb

Recruiting

An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission

Leukemia, Myeloid, Acute

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

Hepatic Insufficiency | Neoplasms

Spain, United States, Germany, Argentina, Colombia, Greece
Novartis Pharmaceuticals

Recruiting

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

Spain, Italy, Malaysia, China, United States, Greece, Brazil
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Acute Myeloid Leukemia

Japan, United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
John Reneau
Bristol-Myers Squibb

Recruiting

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

T-Cell Large Granular Lymphocyte Leukemia

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Angioimmunoblastic T-cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma | Follicular T-Cell Lymphoma | Nodal Peripheral T-Cell Lymphoma...

United States
National Cancer Institute (NCI)

Recruiting

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Lymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditions

United States
University of Virginia
Celgene

Recruiting

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL (PTCL)

PTCL

United States
University of Washington

Recruiting

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Acute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Secondary Myelofibrosis | Myeloproliferative Neoplasm, Unclassifiable

United States
Ottawa Heart Institute Research Corporation

Recruiting

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)

Radial Artery Occlusion

Canada
University of Virginia

Recruiting

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Lymphoma, T-Cell

United States
Novartis Pharmaceuticals

Active, not recruiting

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Myelodysplastic Syndrome (MDS)

United States
University of Birmingham

Active, not recruiting

Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT (AMADEUS)

Acute Myeloid Leukemia | Myelodysplasia

United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Argentina, Canada, France, Germany, Italy, Korea, Republic of, Poland, United States, Australia, China, Czechia, Denmark, Greece, Hong Kong, Japan, Spain, Sweden
University of Florence

Active, not recruiting

Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients (FLO_CC-486-)

MDS | CMML

Italy
Newave Pharmaceutical Inc

Active, not recruiting

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Refractory Acute Lymphoblastic Leukemia | Relapse | CMML | Relapsed Adult AML | AML/MDS | Relapse Leukemia

United States, Spain
H. Lee Moffitt Cancer Center and Research Institute
Secura Bio, Inc.

Active, not recruiting

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

Hodgkin Lymphoma | Non Hodgkin Lymphoma | Myeloma | Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Celgene

Active, not recruiting

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

Metastatic Melanoma | Melanoma and Other Malignant Neoplasms of Skin

United States
The Lymphoma Academic Research Organisation
Celgene

Active, not recruiting

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Relapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell Lymphoma

France, Denmark, United Kingdom, Austria, Belgium
Celgene

Completed

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, United Kingdom, Australia, Poland, Spain, Belgium, Italy, Germany, France, Canada
AbbVie

Terminated

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States, Australia, Germany, Israel, Italy, Japan, Spain
Celgene
AbbVie

Completed

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) (OMNIVERSE)

Leukemia, Myeloid, Acute

United States, Australia
Medical University of South Carolina
Celgene Corporation

Completed

Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

Large B-Cell Diffuse Lymphoma

United States
Celgene

Completed

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
Celgene

Active, not recruiting

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission (QUAZAR AML-001)

Leukemia, Myeloid, Acute

United States, Australia, Brazil, Canada, Czechia, Finland, France, Germany, Italy, Korea, Republic of, Mexico, Portugal, Russian Federation, Spain, United Kingdom, Belgium, Taiwan, Austria, Ireland, Israel, Lithuania, Poland, Turkey
Yale University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Withdrawn

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Acute Myeloid Leukemia

United States
Celgene

Active, not recruiting

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Neoplasms | Hematologic Malignancies | Hematologic Neoplasm

United Kingdom, United States
Sheba Medical Center

Completed

Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients

Prevention

Israel
AbbVie
Roche-Genentech

Active, not recruiting

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

Acute Myeloid Leukemia (AML)

United States, Australia, Canada, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Celgene

Completed

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer (abound2L+)

Carcinoma, Non-Small-Cell Lung

United States, Canada, France, Germany, Italy, Spain, United Kingdom
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Myeloproliferative Neoplasms (MPNs)

United States, Spain, Korea, Republic of, France, Taiwan, Australia, Belgium, Singapore, Israel, Canada, Germany, Finland
Weill Medical College of Cornell University
Celgene Corporation

Completed

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

Previously Untreated Peripheral T-cell Lymphoma

United States
AbbVie
Genentech, Inc.

Active, not recruiting

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

Acute Myeloid Leukemia (AML)

China
Celgene

Active, not recruiting

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Italy, France, Germany, Greece, Spain
Celgene

Active, not recruiting

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Lymphoma, T-Cell

Japan
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)

Pancreatic Cancer

United States

Search clinical trials for: Oral Azacitidine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations